Oxonic Acid-13C2,15N3 (potassium salt hydrate) (Synonyms: Allantoxanic Acid-13C2,15N3, Potassium oxonate-13C2,15N3)

Oxonic acid-¹³C₂,¹⁵N₃ is intended for use as an internal standard for the quantification of oxonic acid (potassium salt) by GC- or LC-MS. Oxonic acid is a uricase inhibitor (IC₅₀ = 0.8 µM) that prevents metabolism and excretion of uric acid.^1,2 It also inhibits orotate phosphoribosyltransferase (ORPT), reducing OPRT-mediated phosphorylation of 5-fluorouracil in Yoshida sarcoma cell extracts with an IC₅₀ value of 3.7 µM.³ Oxonic acid (10-50 mg/kg) decreases the severity of gastrointestinal tract injury and the incidence of diarrhea induced by the 5-FU prodrug tegafur and uracil without loss of antitumor activity in a rat Yoshida sarcoma model. It has also been used to induce hyperuricemia in rodents.⁴ Formulations containing oxonic acid have been used in the treatment of head, neck, lung, pancreatic, gastric, and breast carcinomas.

1.Johnson, W.J., and Chartrand, A.Allantoxanamide: A potent new uricase inhibitor in vivoLife Sci.23(22)2239-2244(1978) 2.Gralla, E.J., and Crelin, E.S.Oxonic acid and fetal development: I. Embryotoxicity in miceToxicology6(3)289-297(1976) 3.Shirasaka, T., Shimamoto, Y., and Fukushima, M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res.53(17)4004-4009(1993) 4.Stavric, B., and Nera, E.A.Use of the uricase-inhibited rat as an animal model in toxicologyClin. Toxicol.13(1)47-74(1978)